| For: | Tzouvala M, Zacharopoulou E, Kalafateli M, Viazis N, Psistakis A, Theodoropoulou A, Drygiannakis I, Karmiris K, Koutroubakis IE, Kevrekidou P, Soufleris K, Katsaros M, Giouleme O, Fousekis F, Katsanos K, Christodoulou D, Gaki A, Papathanasiou E, Bamias G, Zampeli E, Michopoulos S, Kyriakos N, Veretanos C, Argyriou K, Kapsoritakis A, Tribonias G, Mantzaris GJ, Liatsos C. Value of tofacitinib extended induction therapy in patients with moderate-to-severe ulcerative colitis: A real-world 52-week follow-up study. World J Gastroenterol 2025; 31(42): 111282 [PMID: 41278164 DOI: 10.3748/wjg.v31.i42.111282] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v31/i42/111282.htm |
| Number | Citing Articles |
| 1 |
Ahmed S Aboelela, Yasser Fouad. Lessons from extended induction and practical evidence for improving tofacitinib therapy in ulcerative colitis. World Journal of Gastroenterology 2026; 32(9): 115785 doi: 10.3748/wjg.v32.i9.115785
|
